Impact of venous thromboembolism on clinical management and therapy after hip and knee arthroplasty

Canadian Journal of Surgery

Volumn 54, Issue 5, 2011, Pages 344-351

  Fisher, William D ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80053293849     PISSN: 0008428X     EISSN: 14882310     Source Type: Journal    
DOI: 10.1503/cjs.007310     Document Type: Review

References (50)

1. Heit JA, Cohen AT, Anderson FA, et al. Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US [abstract]. Blood 2005;106:267A.
2. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost 2007;98:756-64. (Pubitemid 47555066)
3. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians evidencebased clinical practice guidelines (8th edition). Chest 2008;133(6 Suppl):381S-453S. (Pubitemid 351894916)
4. Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol 2009;29:298-310.
5. Kahn SR. Frequency and determinants of the postthrombotic syndrome after venous thromboembolism. Curr Opin Pulm Med 2006; 12: 299-303. (Pubitemid 44315771)
6. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004;126:338S-400S. (Pubitemid 39302602)
7. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical proced - ures. Thromb Haemost 2003;90:446-55. (Pubitemid 37138770)
8. Warwick D, Friedman RJ, Agnelli G, et al. Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic events: findings from the Global Orthopaedic Registry. J Bone Joint Surg Br 2007;89:799-807. (Pubitemid 47180202)
9. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107:I22-30. (Pubitemid 41289268)
10. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost 2003;1:1504-14.
11. Dahl OE. Mechanisms of hypercoagulability. Thromb Haemost 1999; 82: 902-6.
12. McNally MA, Mollan RA. Total hip replacement, lower limb blood flow and venous thrombogenesis. J Bone Joint Surg Br 1993;75:640-4. (Pubitemid 23222143)
13. McNally MA, Bahadur R, Cooke EA, et al. Venous haemodynamics in both legs after total knee replacement. J Bone Joint Surg Br 1997; 79: 633-7.
14. Dahl OE, Aspelin T, Arnesen H, et al. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery. Thromb Res 1995;80:299-306.
15. Kroegel C, Reissig A. Principle mechanisms underlying venous thromboembolism: epidemiology, risk factors, pathophysiology and pathogenesis. Respiration 2003;70:7-30. (Pubitemid 36216642)
16. Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722-7. (Pubitemid 43973557)
17. Kim YH, Oh SH, Kim JS. Incidence and natural history of deep-vein thrombosis after total hip arthroplasty. A prospective and randomised clinical study. J Bone Joint Surg Br 2003;85:661-5.
18. Stulberg BN, Insall JN, Williams GW, et al. Deep-vein thrombosis following total knee replacement. An analysis of six hundred and thirty-eight arthroplasties. J Bone Joint Surg Am 1984;66:194-201. (Pubitemid 14150384)
19. Cordell-Smith JA, Williams SC, Harper WM, et al. Lower limb arthroplasty complicated by deep venous thrombosis. Prevalence and subjective outcome. J Bone Joint Surg Br 2004;86:99-101. (Pubitemid 38128714)
20. Lindahl TL, Lundahl TH, Nilsson L, et al. APC-resistance is a risk factor for postoperative thromboembolism in elective replacement of the hip or knee - a prospective study. Thromb Haemost 1999;81:18-21. (Pubitemid 29041642)
21. Meltzer ME, Doggen CJ, de Groot PG, et al. The impact of the fibrinolytic system on the risk of venous and arterial thrombosis. Semin Thromb Hemost 2009;35:468-77.
22. Eikelboom JW, Karthikeyan G, Fagel N, et al. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: What are the implications for clinicians and patients? Chest 2009;135:513-20.
23. American Academy of Orthopaedic Surgeons (AAOS). American Academy of Orthopaedic Surgeons clinical guideline on prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. Rosemont (IL): AAOS; 2007. Available: www aaos org/Research /guidelines/PE-guidelinepdf (accessed 2009 Jun. 13).
24. Friedman RJ, Gallus AS, Cushner FD, et al. Physician compliance with guidelines for deep-vein thrombosis prevention in total hip and knee arthroplasty. Curr Med Res Opin 2008;24:87-97. (Pubitemid 351160242)
25. Fisher WD, Turpie AG. Outpatient thromboprophylaxis after hip or knee surgery: discrepancies and concerns. CMAJ 2008;178:1571-2. (Pubitemid 351860343)
26. Kakkar AK, Davidson BL, Haas SK. Compliance with recommended prophylaxis for venous thromboembolism: improving the use and rate of uptake of clinical practice guidelines. J Thromb Haemost 2004; 2: 221-7. (Pubitemid 40186034)
27. Levine MN, Gent M, Hirsh J, et al. Ardeparin (low-molecularweight heparin) vs graduated compression stockings for the prevention of venous thromboembolism. A randomized trial in patients undergoing knee surgery. Arch Intern Med 1996;156:851-6. (Pubitemid 26119812)
28. Eriksson BI, Dahl OE, Rosencher N, et al. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007;370:949-56. (Pubitemid 47393577)
29. Eriksson BI, Dahl OE, Rosencher N, et al. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007;5:2178-85. (Pubitemid 47617868)
30. RE-MOBILIZE Writing Committee; Ginsberg JS, Davidson BL, Comp PC, et al. The oral thrombin inhibitor dabigatran etexilate vs the North American enoxaparin regimen for the prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty 2009;24:1-9.
31. Eikelboom JW, Quinlan DJ, Douketis JD. Extended-duration prophylaxis against venous thromboembolism after total hip or knee replacement: a meta-analysis of the randomised trials. Lancet 2001; 358: 9-15. (Pubitemid 32709732)
32. Turpie AG, Bauer KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies. Arch Intern Med 2002;162:1833-40.
33. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty: a prospect - ive controlled randomized study. Arch Intern Med 2002;162:1966-71.
34. Karwinski B, Svendsen E. Comparison of clinical and postmortem diagnosis of pulmonary embolism. J Clin Pathol 1989;42:135-9. (Pubitemid 19048467)
35. Stangier J, Rathgen K, Stahle H, et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol 2007;64:292-303. (Pubitemid 47283865)
36. Stangier J, Stähle H, Rathgen K, et al. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008;47:47-59. (Pubitemid 350260888)
37. Pradaxa® summary of product characteristics. Germany: Boehringer Ingelheim International GmbH; 2008. Available: http://vte.pradaxa.com/content/ dam/internet/pm/vte/comEN/documents/Pradaxa-SPCEMEA.pdf (accessed 2011 June 17).
38. Eriksson BI, Dahl OE, Huo MH, et al. Oral dabigatran versus enoxaparin for thromboprohylaxis after primary total hip arthroplasty (RENOVATE II). Throm Haemost 2011;105:721-9.
39. Wolowacz SE, Roskell NS, Plumb JM, et al. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Thromb Haemost 2009;101:77-85.
40. Xarelto® summary of product characteristics. Berlin (Germany): Bayer Schering Pharma 2009. Available: www.xarelto.com/html/downloads /Xarelto-Summary-of-Product-Characteristics-May2009.pdf (accessed 2010 Feb. 15).
41. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 2005;78:412-21. (Pubitemid 41393676)
42. Mueck W, Becka M, Kubitza D, et al. Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct Factor Xa inhibitor - in healthy subjects. Int J Clin Pharmacol Ther 2007; 45:335-44. (Pubitemid 46895052)
43. Mueck W, Eriksson BI, Bauer KA, et al. Population pharmacokinetics and pharmacodynamics of rivaroxaban - an oral, direct factor Xa inhibitor - in patients undergoing major orthopaedic surgery. Clin Pharmacokinet 2008;47:203-16.
44. Mueck W, Borris LC, Dahl OE, et al. Population pharmacokinetics and pharmacodynamics of once- and twice-daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement. Thromb Haemost 2008;100:453-61.
45. Eriksson BI, Borris LC, Friedman RJ, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med 2008;358:2765-75. (Pubitemid 351930851)
46. Kakkar AK, Brenner B, Dahl OE, et al. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 2008;372:31-9.
47. Lassen MR, Ageno W, Borris LC, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med 2008;358:2776-86. (Pubitemid 351930852)
48. Turpie AGG, Lassen MR, Davidson BL, et al. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. Lancet 2009;373:1673-80.
49. Turpie AGG, Lassen MR, Kakkar AK, et al. A pooled analysis of four pivotal studies of rivaroxaban for the prevention of venous thromboembolism after orthopaedic surgery: effect on symptomatic venous thromboembolism and death, and bleeding [abstract]. Haematologica 2009;94(Suppl 2):212.
50. Turpie AGG, Lassen MR, Eriksson BI, et al. Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Thromb Haemost 2011;105:444-53.